A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
This study aimed to evaluate the durability of the immunogenicity of MVA85A beyond infancy. Participants in an immunogenicity study of MVA85A administered at age of 4 months had additional evaluation 14 months after initial vaccination for IFN-γ ELISPOT responses to Ag85A peptide and ESAT6/CFP-10 an...
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
2012
|